(Q50525085)

14 March 2018

title

Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers (English)

1 reference

14 March 2018

1 reference

1 reference

6

William L Klein

1 reference

14 March 2018

author name string

Tomohiro Umeda

1

1 reference

14 March 2018

Kenjiro Ono

2

1 reference

14 March 2018

Ayumi Sakai

3

1 reference

14 March 2018

Minato Yamashita

4

1 reference

14 March 2018

Mineyuki Mizuguchi

5

1 reference

14 March 2018

Masahito Yamada

7

1 reference

14 March 2018

Hiroshi Mori

8

1 reference

14 March 2018

Takami Tomiyama

9

1 reference

14 March 2018

language of work or name

English

0 references

publication date

28 March 2016

1 reference

14 March 2018

published in

Brain

1 reference

14 March 2018

volume

139

1 reference

14 March 2018

issue

Pt 5

1 reference

14 March 2018

page(s)

1568-1586

1 reference

14 March 2018

Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Synucleinopathies: clinical and pathological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Autophagy and apoptosis dysfunction in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Physiological significance of selective degradation of p62 by autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Monoclonal antibodies that target pathological assemblies of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Neurodegenerative tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

The E693Δ (Osaka) mutation in amyloid precursor protein potentiates cholesterol-mediated intracellular amyloid β toxicity via its impaired cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Structure-neurotoxicity relationships of amyloid beta-protein oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Amyloid ion channels: a common structural link for protein-misfolding disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Testing the right target and right drug at the right stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Targeting autophagy in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Tau aggregation is driven by a transition from random coil to beta sheet structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWW042

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWW042

1 reference

14 March 2018

1 reference

14 March 2018